)
Visual
test
Race Oncology
Race Oncology (RAC) investor relations material
Race Oncology Q2 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 TU earnings summary28 Jan, 2026
Executive summary
(E,E)-bisantrene discovered to act by binding to G4-DNA & RNA, not as a doxorubicin-like chemotherapeutic, fundamentally transforming commercial and clinical opportunities.
Clinical programs expanded for RC220 in lung cancer, solid tumours, and acute myeloid leukaemia, targeting major cancer markets.
Composition of matter patent claims filed for (E,E)-bisantrene, potentially providing 20 years of protection.
Appointment of Prof. Laurence Hurley to Scientific Advisory Board, strengthening expertise in G4-targeting drugs.
Company name changed from Race Oncology Limited to Racura Oncology Ltd.
Financial highlights
Cash and cash equivalents of $20.94 million at 31 December 2025.
Private placement raised $3.22 million at a premium to market; early option conversions added $5.62 million.
R&D and drug manufacturing accounted for over 63% of spending ($1.35 million) in the quarter.
Received $2.79 million R&D Tax Incentive from the Australian Taxation Office for FY2025.
Outlook and guidance
Funding secured to support all committed activities through calendar year 2027.
HARNESS-1 Phase 1a/b trial in EGFRm NSCLC to commence in early 2026, with additional sites to be activated in H1 CY2026.
Preclinical collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant NSCLC expected to last over 12 months.
How does G4-DNA/RNA MOA refine target cancers?
What's the strategy for AML regulatory approval?
Address patent novelty objections for (E,E)-bisantrene
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- SANSERA
Q1 FY25 delivered double-digit growth, margin expansion, and a record order book despite global headwinds. - JKHY
Record revenue, margin, and EPS growth drive raised guidance and strong segment momentum. - IEX
Record HST-driven growth and margin gains support 2026 outlook amid industrial headwinds. - KREF
Net loss for 2025, but strong liquidity, portfolio repositioning, and active capital management. - ODFL
Q4 revenue and earnings declined, but yield, service, and capital returns remained strong. - ORN
Acquisition expands marine construction scale and reach, supporting long-term profitable growth. - THG
Record earnings, improved underwriting, and strong capital actions drive robust 2025 results. - BAM
Record earnings, 15% dividend increase, and major AI initiatives drive robust growth. - LLY
Q4 2025 revenue up 43% to $19.3B; 2026 guidance: $80–$83B revenue, $33.50–$35 EPS. - CDW
2025 sales and profits rose, with strong cash returns and 2026 growth set to outpace the market.
Next Race Oncology earnings date
Q3 202621 Apr, 2026
Race Oncology
Next Race Oncology earnings date
Q3 202621 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Race Oncology Limited is an Australian-based pharmaceutical company focused on the development and commercialization of oncology therapies. The company is dedicated to researching and advancing treatments for cancer, particularly through its drug discovery and development programs. Race Oncology employs precision medicine approaches and targets specific cancer-related pathways to address unmet needs in cancer care. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage